APO RESEARCH · REPORT
Circulating Tumor Cells
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.
Product & engineering
Understand the product.
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.
Selected research
Industry Research
Circulating Tumor Cells Industry Research Report 2026
Market perspective
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.
Global Circulating Tumor Cells main players are Menarini-Silicon Biosystems, Qiagen（Adnagen）, Clearbridge Biomedics, Celsee, Fluidigm. Global top five manufacturers hold a share over 30%.
Report Scope
Read the full market overview
This report quantifies the global Circulating Tumor Cells market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Circulating Tumor Cells.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Circulating Tumor Cells Market by Company
Menarini-Silicon Biosystems
Qiagen (Adnagen)
Advanced Cell Diagnostics
ApoCell
Epic Sciences
Greiner Bio-one GmbH
Cynvenio
SurExamBio-Tech
Fluxion Biosciences
Ikonisys
Hangzhou Watson Biotech
Biocept
CytoTrack
Guangzhou Wondfo Biotech
Celsee
Clearbridge Biomedics
ANGLE plc
Circulating Tumor Cells Segment by Type
CTC Enrichment
CTC Detection
CTC Analysis
Circulating Tumor Cells Segment by Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Lung Cancer
Others
Circulating Tumor Cells Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Circulating Tumor Cells market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Circulating Tumor Cells and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Circulating Tumor Cells.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Circulating Tumor Cells companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CTC Enrichment
- CTC Detection
- CTC Analysis
Applications
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Lung Cancer
- Others
Companies covered
- Menarini-Silicon Biosystems
- Qiagen (Adnagen)
- Advanced Cell Diagnostics
- ApoCell
- Epic Sciences
- Greiner Bio-one GmbH
- Cynvenio
- SurExamBio-Tech
- Fluxion Biosciences
- Ikonisys
- Hangzhou Watson Biotech
- Biocept
- CytoTrack
- Guangzhou Wondfo Biotech
- Celsee
- Clearbridge Biomedics
- ANGLE plc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Circulating Tumor Cells by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 CTC Enrichment
- 2.2.3 CTC Detection
- 2.2.4 CTC Analysis
- 2.3 Circulating Tumor Cells by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Breast Cancer
- 2.3.3 Prostate Cancer
- 2.3.4 Colorectal Cancer
- 2.3.5 Lung Cancer
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Circulating Tumor Cells Breakdown Data by Type
- 3.1 Global Circulating Tumor Cells Historic Market Size by Type (2021-2026)
- 3.2 Global Circulating Tumor Cells Forecasted Market Size by Type (2027-2032)
4 Circulating Tumor Cells Breakdown Data by Application
- 4.1 Global Circulating Tumor Cells Historic Market Size by Application (2021-2026)
- 4.2 Global Circulating Tumor Cells Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Circulating Tumor Cells Market Perspective (2021-2032)
- 5.2 Global Circulating Tumor Cells Growth Trends by Region
- 5.2.1 Global Circulating Tumor Cells Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Circulating Tumor Cells Historic Market Size by Region (2021-2026)
- 5.2.3 Circulating Tumor Cells Forecasted Market Size by Region (2027-2032)
- 5.3 Circulating Tumor Cells Market Dynamics
- 5.3.1 Circulating Tumor Cells Industry Trends
- 5.3.2 Circulating Tumor Cells Market Drivers
- 5.3.3 Circulating Tumor Cells Market Challenges
- 5.3.4 Circulating Tumor Cells Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Circulating Tumor Cells Players by Revenue
- 6.1.1 Global Top Circulating Tumor Cells Players by Revenue (2021-2026)
- 6.1.2 Global Circulating Tumor Cells Revenue Market Share by Players (2021-2026)
- 6.2 Global Circulating Tumor Cells Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Circulating Tumor Cells Head Office and Area Served
- 6.4 Global Circulating Tumor Cells Players, Product Type & Application
- 6.5 Global Circulating Tumor Cells Manufacturers Established Date
- 6.6 Global Circulating Tumor Cells Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Circulating Tumor Cells Market Size (2021-2032)
- 7.2 North America Circulating Tumor Cells Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Circulating Tumor Cells Market Size by Country (2021-2026)
- 7.4 North America Circulating Tumor Cells Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Circulating Tumor Cells Market Size (2021-2032)
- 8.2 Europe Circulating Tumor Cells Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Circulating Tumor Cells Market Size by Country (2021-2026)
- 8.4 Europe Circulating Tumor Cells Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Circulating Tumor Cells Market Size (2021-2032)
- 9.2 Asia-Pacific Circulating Tumor Cells Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Circulating Tumor Cells Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Circulating Tumor Cells Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Circulating Tumor Cells Market Size (2021-2032)
- 10.2 South America Circulating Tumor Cells Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Circulating Tumor Cells Market Size by Country (2021-2026)
- 10.4 South America Circulating Tumor Cells Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Circulating Tumor Cells Market Size (2021-2032)
- 11.2 Middle East & Africa Circulating Tumor Cells Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Circulating Tumor Cells Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Circulating Tumor Cells Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Menarini-Silicon Biosystems
- 12.1.1 Menarini-Silicon Biosystems Company Information
- 12.1.2 Menarini-Silicon Biosystems Business Overview
- 12.1.3 Menarini-Silicon Biosystems Revenue in Circulating Tumor Cells Business (2021-2026)
- 12.1.4 Menarini-Silicon Biosystems Circulating Tumor Cells Product Portfolio
- 12.1.5 Menarini-Silicon Biosystems Recent Developments
- 12.2 Qiagen (Adnagen)
- 12.2.1 Qiagen (Adnagen) Company Information
- 12.2.2 Qiagen (Adnagen) Business Overview
- 12.2.3 Qiagen (Adnagen) Revenue in Circulating Tumor Cells Business (2021-2026)
- 12.2.4 Qiagen (Adnagen) Circulating Tumor Cells Product Portfolio
- 12.2.5 Qiagen (Adnagen) Recent Developments
- 12.3 Advanced Cell Diagnostics
- 12.3.1 Advanced Cell Diagnostics Company Information
- 12.3.2 Advanced Cell Diagnostics Business Overview
- 12.3.3 Advanced Cell Diagnostics Revenue in Circulating Tumor Cells Business (2021-2026)
- 12.3.4 Advanced Cell Diagnostics Circulating Tumor Cells Product Portfolio
- 12.3.5 Advanced Cell Diagnostics Recent Developments
- 12.4 ApoCell
- 12.4.1 ApoCell Company Information
- 12.4.2 ApoCell Business Overview
- 12.4.3 ApoCell Revenue in Circulating Tumor Cells Business (2021-2026)
- 12.4.4 ApoCell Circulating Tumor Cells Product Portfolio
- 12.4.5 ApoCell Recent Developments
- 12.5 Epic Sciences
- 12.5.1 Epic Sciences Company Information
- 12.5.2 Epic Sciences Business Overview
- 12.5.3 Epic Sciences Revenue in Circulating Tumor Cells Business (2021-2026)
- 12.5.4 Epic Sciences Circulating Tumor Cells Product Portfolio
- 12.5.5 Epic Sciences Recent Developments
- 12.6 Greiner Bio-one GmbH
- 12.6.1 Greiner Bio-one GmbH Company Information
- 12.6.2 Greiner Bio-one GmbH Business Overview
- 12.6.3 Greiner Bio-one GmbH Revenue in Circulating Tumor Cells Business (2021-2026)
- 12.6.4 Greiner Bio-one GmbH Circulating Tumor Cells Product Portfolio
- 12.6.5 Greiner Bio-one GmbH Recent Developments
- 12.7 Cynvenio
- 12.7.1 Cynvenio Company Information
- 12.7.2 Cynvenio Business Overview
- 12.7.3 Cynvenio Revenue in Circulating Tumor Cells Business (2021-2026)
- 12.7.4 Cynvenio Circulating Tumor Cells Product Portfolio
- 12.7.5 Cynvenio Recent Developments
- 12.8 SurExamBio-Tech
- 12.8.1 SurExamBio-Tech Company Information
- 12.8.2 SurExamBio-Tech Business Overview
- 12.8.3 SurExamBio-Tech Revenue in Circulating Tumor Cells Business (2021-2026)
- 12.8.4 SurExamBio-Tech Circulating Tumor Cells Product Portfolio
- 12.8.5 SurExamBio-Tech Recent Developments
- 12.9 Fluxion Biosciences
- 12.9.1 Fluxion Biosciences Company Information
- 12.9.2 Fluxion Biosciences Business Overview
- 12.9.3 Fluxion Biosciences Revenue in Circulating Tumor Cells Business (2021-2026)
- 12.9.4 Fluxion Biosciences Circulating Tumor Cells Product Portfolio
- 12.9.5 Fluxion Biosciences Recent Developments
- 12.10 Ikonisys
- 12.10.1 Ikonisys Company Information
- 12.10.2 Ikonisys Business Overview
- 12.10.3 Ikonisys Revenue in Circulating Tumor Cells Business (2021-2026)
- 12.10.4 Ikonisys Circulating Tumor Cells Product Portfolio
- 12.10.5 Ikonisys Recent Developments
- 12.11 Hangzhou Watson Biotech
- 12.11.1 Hangzhou Watson Biotech Company Information
- 12.11.2 Hangzhou Watson Biotech Business Overview
- 12.11.3 Hangzhou Watson Biotech Revenue in Circulating Tumor Cells Business (2021-2026)
- 12.11.4 Hangzhou Watson Biotech Circulating Tumor Cells Product Portfolio
- 12.11.5 Hangzhou Watson Biotech Recent Developments
- 12.12 Biocept
- 12.12.1 Biocept Company Information
- 12.12.2 Biocept Business Overview
- 12.12.3 Biocept Revenue in Circulating Tumor Cells Business (2021-2026)
- 12.12.4 Biocept Circulating Tumor Cells Product Portfolio
- 12.12.5 Biocept Recent Developments
- 12.13 CytoTrack
- 12.13.1 CytoTrack Company Information
- 12.13.2 CytoTrack Business Overview
- 12.13.3 CytoTrack Revenue in Circulating Tumor Cells Business (2021-2026)
- 12.13.4 CytoTrack Circulating Tumor Cells Product Portfolio
- 12.13.5 CytoTrack Recent Developments
- 12.14 Guangzhou Wondfo Biotech
- 12.14.1 Guangzhou Wondfo Biotech Company Information
- 12.14.2 Guangzhou Wondfo Biotech Business Overview
- 12.14.3 Guangzhou Wondfo Biotech Revenue in Circulating Tumor Cells Business (2021-2026)
- 12.14.4 Guangzhou Wondfo Biotech Circulating Tumor Cells Product Portfolio
- 12.14.5 Guangzhou Wondfo Biotech Recent Developments
- 12.15 Celsee
- 12.15.1 Celsee Company Information
- 12.15.2 Celsee Business Overview
- 12.15.3 Celsee Revenue in Circulating Tumor Cells Business (2021-2026)
- 12.15.4 Celsee Circulating Tumor Cells Product Portfolio
- 12.15.5 Celsee Recent Developments
- 12.16 Clearbridge Biomedics
- 12.16.1 Clearbridge Biomedics Company Information
- 12.16.2 Clearbridge Biomedics Business Overview
- 12.16.3 Clearbridge Biomedics Revenue in Circulating Tumor Cells Business (2021-2026)
- 12.16.4 Clearbridge Biomedics Circulating Tumor Cells Product Portfolio
- 12.16.5 Clearbridge Biomedics Recent Developments
- 12.17 ANGLE plc
- 12.17.1 ANGLE plc Company Information
- 12.17.2 ANGLE plc Business Overview
- 12.17.3 ANGLE plc Revenue in Circulating Tumor Cells Business (2021-2026)
- 12.17.4 ANGLE plc Circulating Tumor Cells Product Portfolio
- 12.17.5 ANGLE plc Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst